| scholarly article | Q13442814 |
| P50 | author | Luc Maroteaux | Q42416039 |
| Laurent Monassier | Q47172398 | ||
| P2093 | author name string | Fabrice Jaffré | |
| Nadia Messaddeq | |||
| Jean-Marie Launay | |||
| Canan G Nebigil | |||
| Pierre Hickel | |||
| P433 | issue | 25 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | serotonin | Q167934 |
| overexpression | Q61643320 | ||
| P304 | page(s) | 3223-3229 | |
| P577 | publication date | 2003-06-16 | |
| P1433 | published in | Circulation | Q578091 |
| P1476 | title | Overexpression of the serotonin 5-HT2B receptor in heart leads to abnormal mitochondrial function and cardiac hypertrophy | |
| P478 | volume | 107 |
| Q88915324 | 5-HT1F receptor regulates mitochondrial homeostasis and its loss potentiates acute kidney injury and impairs renal recovery |
| Q53657799 | 5-HT2B receptor blockade attenuates β-adrenergic receptor-stimulated myocardial remodeling in rats via inhibiting apoptosis: role of MAPKs and HSPs. |
| Q33613615 | 5-hydroxytryptamine receptor stimulation of mitochondrial biogenesis |
| Q24309030 | A new class of 5-HT2B antagonists possesses favorable potency, selectivity, and rat pharmacokinetic properties |
| Q28572337 | A small molecular activator of cardiac hypertrophy uncovered in a chemical screen for modifiers of the calcineurin signaling pathway |
| Q36807865 | Alteration of gene expression during progression of hypertension-induced cardiac dysfunction in rats |
| Q54567679 | Altered expression of a limited number of genes contributes to cardiac decompensation during chronic ventricular tachypacing in dogs. |
| Q46367159 | Cambridge Healthtech Institute Signal Transduction Conference: targets for effective therapeutics |
| Q58801185 | Carcinoid syndrome: update on the pathophysiology and treatment |
| Q47777271 | Cardiac Outcomes After Perinatal Sertraline Exposure in Mice. |
| Q35049986 | Cardiac progenitor cell cycling stimulated by pim-1 kinase |
| Q38521958 | Cardiac transcriptional response to acute and chronic angiotensin II treatments |
| Q28068096 | Complications from carcinoid syndrome: review of the current evidence |
| Q46784507 | Degeneration of serotonergic neurons in amyotrophic lateral sclerosis: a link to spasticity |
| Q38100690 | Distinct signaling pathways activated by "extracellular" and "intracellular" serotonin in heart valve development and disease. |
| Q38571768 | Emotional triggering of cardiac dysfunction: the present and future |
| Q57823442 | G-Protein-Coupled Receptors in Heart Disease |
| Q46151811 | Genetic deletion of MAO-A promotes serotonin-dependent ventricular hypertrophy by pressure overload |
| Q34519433 | Granule cargo release from bone marrow-derived cells sustains cardiac hypertrophy |
| Q50879823 | In utero exposure to venlafaxine, a serotonin-norepinephrine reuptake inhibitor, increases cardiac anomalies and alters placental and heart serotonin signaling in the rat. |
| Q47639140 | Inhibition of 5-Hydroxytryptamine Receptor 2B Reduced Vascular Restenosis and Mitigated the β-Arrestin2-Mammalian Target of Rapamycin/p70S6K Pathway |
| Q33780802 | Lack of serotonin 5-HT2B receptor alters proliferation and network volume of interstitial cells of Cajal in vivo. |
| Q37264205 | Merkel disc is a serotonergic synapse in the epidermis for transmitting tactile signals in mammals |
| Q33723676 | Monoamine oxidases as sources of oxidants in the heart |
| Q47720153 | Neuroendocrine tumors and fibrosis: An unsolved mystery? |
| Q36808706 | New insights on receptor-dependent and monoamine oxidase-dependent effects of serotonin in the heart. |
| Q36262381 | Prolonged Activation of the Htr2b Serotonin Receptor Impairs Glucose Stimulated Insulin Secretion and Mitochondrial Function in MIN6 Cells |
| Q37371993 | Protein kinase C{gamma} mediates regulation of proliferation by the serotonin 5-hydroxytryptamine receptor 2B. |
| Q46123284 | Regulatory mechanism of CCN2 production by serotonin (5-HT) via 5-HT2A and 5-HT2B receptors in chondrocytes. |
| Q45936037 | Role of the serotonin transporter in heart valve development and disease. |
| Q38173201 | Safety Pharmacology assessment of drugs with biased 5-HT(2B) receptor agonism mediating cardiac valvulopathy |
| Q49026083 | Serotonin 2B receptor slows disease progression and prevents degeneration of spinal cord mononuclear phagocytes in amyotrophic lateral sclerosis |
| Q24316322 | Serotonin and angiotensin receptors in cardiac fibroblasts coregulate adrenergic-dependent cardiac hypertrophy |
| Q35847080 | Serotonin and blood pressure regulation |
| Q47131270 | Serotonin drives the acquisition of a profibrotic and anti-inflammatory gene profile through the 5-HT7R-PKA signaling axis. |
| Q38231265 | Serotonin modulation of macrophage polarization: inflammation and beyond |
| Q38049023 | Serotonin paracrine signaling in tissue fibrosis |
| Q34173511 | Serotonin receptors and heart valve disease--it was meant 2B. |
| Q46950614 | Serotonin responsiveness through 5-HT2A and 5-HT4 receptors is differentially regulated in hypertrophic and failing rat cardiac ventricle |
| Q34429191 | The cardiac ventricular 5-HT4 receptor is functional in late foetal development and is reactivated in heart failure |
| Q54227312 | The potential role of myocardial serotonin receptor 2B expression in canine dilated cardiomyopathy. |
| Q33683749 | Toward transcriptional therapies for the failing heart: chemical screens to modulate genes |
| Q36815987 | Vasoactive peptides in cardiovascular (patho)physiology. |
Search more.